Nabriva began a Phase I trial of topical BC-7013. Nabriva Therapeutics Forschungs GmbH , Vienna, Austria   Product: BC-7013   Business: Infectious   Molecular target: NA   Description: Pleuromutilin antibiotic agent   Indication: Treat bacterial infections...